<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Adults with systolic heart failure.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Adults with systolic heart failure. Southfield (MI): Michigan Quality Improvement Consortium; 2013 Jan. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Adults with systolic heart failure. Southfield (MI): Michigan Quality Improvement Consortium; 2011 Jan. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Congestive heart failure, unspecified  (428.0); Diagnostic ultrasound of heart  (88.72); Electrocardiogram  (89.52); General physical examination  (89.7); Heart failure, unspecified  (428.9); Heart transplantation  (37.51); Organ or tissue replaced by other means, heart assist device  (V43.21); Systolic heart failure, unspecified  (428.20)"/><FieldValue Value="MSH: Adrenergic beta-Antagonists ; Advance Directives ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Bisoprolol ; Blood Cell Count ; Blood Chemical Analysis ; Blood Glucose ; Blood Pressure Determination ; Blood Urea Nitrogen ; Body Weight ; Carbazoles ; Defibrillators, Implantable ; Diagnostic Techniques, Cardiovascular ; Diet, Sodium-Restricted ; Diuretics ; Echocardiography ; Echocardiography, Doppler ; Electrocardiography ; Exercise ; Goals ; Heart Failure ; Heart Failure, Systolic ; Heart Transplantation ; Heart-Assist Devices ; Hydralazine ; Influenza Vaccines ; Isosorbide Dinitrate ; Kidney Function Tests ; Liver Function Tests ; Medical History Taking ; Medication Therapy Management ; Metoprolol ; Patient Compliance ; Patient Education as Topic ; Physical Examination ; Pneumococcal Vaccines ; Prognosis ; Propanolamines ; Risk Assessment ; Risk Factors ; Risk Reduction Behavior ; Self Care ; Smoking Cessation ; Spironolactone ; Urinalysis ; Ventricular Dysfunction, Left "/><FieldValue Value="MTH: Adrenergic beta-Antagonists ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; blood cell count ; Blood Chemical Analysis ; Blood Glucose ; Blood glucose measurement ; Blood pressure determination ; Blood urea nitrogen measurement ; Body Weight ; Cessation of smoking ; complete blood count ; Compliance behavior ; Congestive heart failure ; Creatinine measurement, serum (procedure) ; Depression screen ; Echocardiography ; Echocardiography, Doppler ; Electrocardiogram ; Electrocardiography ; Electrolytes measurement, serum ; Exercise ; Forecast of outcome ; Heart failure ; Heart Transplantation ; Implantable defibrillator ; Influenza virus vaccine ; Isosorbide Dinitrate ; Kidney Function Tests ; Liver Function Tests ; Low sodium diet ; objective (goal) ; Patient education (procedure) ; physical examination ; Plain chest X-ray ; Pneumococcal vaccine ; Risk Assessment ; risk factors ; Self-care interventions ; Serum calcium measurement ; Serum magnesium measurement ; Spironolactone ; Thyroid stimulating hormone measurement ; urinalysis ; Weighing patient "/><FieldValue Value="PDQ: spironolactone "/><FieldValue Value="SNOMEDCT_US: Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Assessment for risk of cardiovascular disease  (441829007); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Bisoprolol  (108547003); Bisoprolol  (386868003); Blood cell count  (88308000); Blood chemistry  (166312007); Blood pressure taking  (46973005); Blood urea nitrogen measurement  (105011006); Blood urea nitrogen measurement  (250623007); Body weight  (27113001); Carvedilol  (108551001); Carvedilol  (386870007); Complete blood count  (26604007); Compliance behavior  (405078008); Congestive heart failure  (42343007); Creatinine measurement, serum  (113075003); Depression screening  (171207006); Determination of prognosis  (20481000); Diuretic  (30492008); Diuretic  (372695000); Echocardiography  (40701008); Education about alcohol consumption  (281078001); Electrocardiographic procedure  (29303009); Electrolytes measurement, serum  (20109005); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fasting lipid profile  (252150008); Glucose measurement, blood  (33747003); Goal  (410518001); Heart failure  (84114007); Hydralazine  (22696000); Hydralazine  (387125005); Implantable defibrillator  (72506001); Implantation of biventricular cardiac pacemaker system  (429064006); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Informing patient of prognosis  (310868002); Isosorbide dinitrate  (387332007); Isosorbide dinitrate  (5924003); Liver function tests - general  (26958001); Liver function tests - general  (271552009); Low sodium diet  (386619000); Low sodium diet  (437421000124105); Magnesium measurement, serum  (63571001); Metoprolol  (372826007); Metoprolol  (7092007); Patient education  (311401005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Plain chest X-ray  (399208008); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Prognosis counseling  (310359007); Propanolamine  (441338003); Renal function study  (44277000); Risk assessment  (225338004); Risk factor  (80943009); Self-care interventions  (384758001); Serum calcium measurement  (271240001); Spironolactone  (13929005); Spironolactone  (387078006); Systolic heart failure  (417996009); Thyroid stimulating hormone measurement  (61167004); Transplantation of heart  (32413006); Urinalysis  (167217005); Urinalysis  (27171005); Ventricular assist device  (360064003); Weighing patient  (39857003)"/><FieldValue Value="SPN: CARDIOCONVERTER, IMPLANTABLE "/><FieldValue Value="UMD: Circulatory Assist Units, Cardiac, Ventricular  (10-847); Defibrillator/Cardioverter/Pacemakers, Implantable  (18-504); Defibrillators, Implantable  (16-652); Defibrillators, Implantable  (18-503); Physiologic Monitor Modules, Electrocardiography  (20-771); Scanning Systems, Ultrasonic, Cardiac  (17-422)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Left-ventricular systolic dysfunction&lt;/li&gt;&#xA;    &lt;li&gt;Systolic heart failure&lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Plans" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To achieve significant, measurable improvements in the management of left-ventricular systolic dysfunction, including systolic heart failure, through the development and implementation of common evidence-based clinical practice guidelines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To design concise guidelines that are focused on key management components of left-ventricular systolic dysfunction, including systolic heart failure, to improve outcomes &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults with suspected or diagnosed left-ventricular systolic dysfunction, including heart failure&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation/Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;History and physical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depression screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment for coronary artery disease and risk factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chest x-ray &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;12-lead electrocardiogram &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory tests including lipid profile, complete blood count (CBC), serum electrolytes, calcium, magnesium, blood urea nitrogen (BUN), serum creatinine, blood glucose, liver function tests, thyroid-stimulating hormone (TSH), and urinalysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Echocardiography with Doppler &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serial monitoring including weight, volume status, electrolytes, renal function, and activity tolerance &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Beta-blockers (carvedilol, sustained-release metoprolol, bisoprolol) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diuretics and sodium restriction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Spironolactone &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin receptor blockers (ARBs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hydralazine and isosorbide dinitrate &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Education/Counseling/Risk Factor Modification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Careful review of medication regimen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Daily self-monitoring of weight and&amp;nbsp;adherence to patient action plan &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptom recognition &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dietary sodium restriction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk factor modification (regular exercise; smoking cessation; control of blood pressure, diabetes mellitus, lipids, etc.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoidance of excessive alcohol intake, illicit drug use, and use of non-steroidal anti-inflammatory drugs (NSAIDs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vaccination against influenza and pneumococcal disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral for evaluation for implantable defibrillator, biventricular pacemaker, ventricular assist device, or transplant &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to an advanced heart failure management program &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discussing goals of care, prognosis, and advanced directives &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Michigan Quality Improvement Consortium (MQIC) health care analyst conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies, existing protocols and/or national guidelines on the selected topic developed by organizations such as the American Diabetes Association, American Heart Association, American Academy of Pediatrics, etc. If available, clinical practice guidelines from participating MQIC health plans and Michigan health systems are also used to develop a framework for the new guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For this guideline update, PubMed, Google, and the American Heart Association and American College of Cardiology Foundation databases were searched from January 1, 2009, to October 31, 2012. No inclusion/exclusion criteria were used. Search terms included spironolactone, LVEF, and heart failure assistive devices.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ol start=&quot;1&quot; type=&quot;A&quot;&gt;&#xD;&#xA;&lt;li&gt;Randomized controlled trials&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Controlled trials, no randomization&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Observational studies&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Opinion of expert panel&lt;/li&gt;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Using information obtained from literature searches and available health plan guidelines on the designated topic, the Michigan Quality Improvement Consortium (MQIC) health care analyst prepares a draft guideline to be reviewed by the Medical Directors' Committee at one of their scheduled meetings. Priority is given to recommendations with [A] and [B] levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial draft guideline is reviewed, evaluated, and revised by the committee resulting in draft two of the guideline. Additionally, the Michigan Academy of Family Physicians participates in guideline development at the onset of the process and throughout the guideline development procedure. The MQIC guideline feedback form and draft two of the guideline are distributed to the Medical Directors, as well as the MQIC measurement and implementation group members, for review and comments. Feedback from members is collected by the MQIC health care analyst and prepared for review by the Medical Directors' Committee at their next scheduled meeting. The review, evaluation, and revision process with several iterations of the guideline may be repeated over several meetings before consensus is reached on a final draft guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When consensus is reached on the final draft guideline, the Medical Directors approve the guideline for external distribution to practitioners with review and comments requested via the Michigan Quality Improvement Consortium (MQIC) health plans (health care analyst distributes final draft to Medical Directors' Committee, measurement and implementation groups to solicit feedback).&lt;/p&gt;&#xA;&lt;p&gt;The MQIC health care analyst also forwards the approved guideline draft to appropriate state medical specialty societies and physicians with expertise in the related field for their input. After all feedback is received from external reviews, it is presented for discussion at the next scheduled committee meeting. Based on feedback, subsequent guideline review, evaluation, and revision may be required prior to final guideline approval.&lt;/p&gt;&#xA;&lt;p&gt;The MQIC Medical Directors approved this updated guideline in January 2013.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The level of evidence grades (&lt;strong&gt;A-D&lt;/strong&gt;) are provided for the most significant recommendations and are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Adults with Suspicion of Left Ventricular Systolic Dysfunction, Including Heart Failure&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Initial assessment should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Thorough history and physical examination &lt;strong&gt;[C]&lt;/strong&gt;, including depression screening, and assessment for coronary artery disease and risk factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Testing includes: chest x-ray, 12-lead electrocardiogram, lipid profile, complete blood count (CBC), electrolytes, calcium, magnesium, blood urea nitrogen (BUN), creatinine, blood glucose, liver function tests, thyroid-stimulating hormone (TSH), urinalysis, and echocardiography with Doppler &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serial monitoring should include: weight, volume status, electrolytes, renal function, and activity tolerance &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Adults Diagnosed with Left Ventricular Systolic Dysfunction, Including Heart Failure&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pharmacological Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;&lt;/em&gt;: Please refer to the &quot;Contraindications&quot; field in this summary and/or the original guideline document for information on contraindications to these medications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Drugs recommended for routine use:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitors in all patients, unless contraindicated &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Beta-blockade using carvedilol, sustained-release metoprolol, bisoprolol in all stable patients, unless contraindicated &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Drugs recommended for use in select patients:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diuretics and sodium restriction for evidence of fluid retention &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Spironolactone for patients with moderate or severe symptoms of heart failure, preserved renal function (creatinine &amp;lt;2.0 in women; creatinine &amp;lt;2.5 in men), and normal serum potassium concentration &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients who cannot tolerate ACE inhibitors due to cough or angioedema, use angiotensin receptor blockers (ARBs) &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider hydralazine and isosorbide dinitrate for patients who cannot tolerate ACE inhibitors or ARBs, or African-American patients who remain symptomatic despite therapy &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Education, Counseling and Risk Factor Modification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Educate patient and family regarding:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Careful review of medication regimen with patient and caregivers at hospitalization or other changes in treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Daily self-monitoring of weight and adherence to recommended patient action plan &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recognition of symptoms and when to seek medical attention &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate dietary sodium restriction (e.g., 2,000 to 2,500 mg sodium/day) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk factor modification (regular exercise 5 times per week as tolerated &lt;strong&gt;[B]&lt;/strong&gt;; smoking cessation; control of blood pressure, diabetes mellitus, lipids) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoid excessive alcohol intake, illicit drug use, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vaccination against influenza and pneumococcal disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider referral for evaluation for implantable defibrillator, ventricular assist device or transplant in patients with left ventricular ejection fraction (LVEF) &amp;lt;35%, New York Heart Association (NYHA) Class III-V patients and those with worsening congestive heart failure (CHF) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider referral to an advanced heart failure management program &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discuss goals of care, prognosis and advance directives with all patients &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is provided for the most significant recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is based on the 2009 Focused Update: American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration with the International Society for Heart and Lung Transplantation.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for left-ventricular systolic dysfunction, including heart failure, Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adverse reactions to medications&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Angiotensin-converting enzyme (ACE) inhibitors&lt;/strong&gt;: Life-threatening adverse reactions (angioedema or anuric renal failure), pregnancy, hypotensive patients at immediate risk of cardiogenic shock, systolic blood pressure &amp;lt;80 mm Hg, serum creatinine &amp;gt;3 mg/dL, bilateral renal artery stenosis, or serum potassium &amp;gt;5.5 mmol/L &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Beta-blockers&lt;/strong&gt;: Life-threatening adverse reactions (angioedema or anuric renal failure), pregnancy, hypotensive patients at immediate risk of cardiogenic shock, systolic blood pressure &amp;lt;80 mm Hg, serum creatinine &amp;gt;3 mg/dL, bilateral renal artery stenosis, or serum potassium &amp;gt;5.5 mmol/L, current or recent fluid retention history, unstable or poorly controlled reactive airway disease, symptomatic bradycardia or advanced heart block (unless treated with a pacemaker), or recent treatment with an intravenous positive inotropic agent &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Individual patient considerations and advances in medical science may supersede or modify these recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Approved Michigan Quality Improvement Consortium (MQIC) guidelines are disseminated through email, U.S. mail, and websites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst prepares approved guidelines for distribution. Portable Document Format (PDF) versions of the guidelines are used for distribution.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst distributes approved guidelines to MQIC membership via email.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to website vendor to post approved guidelines to MQIC website (&lt;a href=&quot;http://www.mqic.org&quot; title=&quot;MQIC Web site&quot;&gt;www.mqic.org&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst completes an annual statewide postcard mailing to physicians in all areas of medicine including primary care and specialties. The postcard provides the complete list of MQIC guidelines and includes which guidelines have been recently revised, which are coming up for revision, and any new published guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The statewide mailing list is derived from the Blue Cross Blue Shield of Michigan (BCBSM) provider database. Approximately 95% of the state's M.D.'s and 96% of the state's D.O.'s are included in the database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to the National Guideline Clearinghouse (NGC) to post approved guidelines to NGC website (&lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;www.guideline.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Adults with systolic heart failure. Southfield (MI): Michigan Quality Improvement Consortium; 2013 Jan. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on the 2009 Focused Update: American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration with the International Society for Heart and Lung Transplantation.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2002 Dec (revised 2013 Jan)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Michigan Quality Improvement Consortium - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium Medical Directors' Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Physician representatives from the 13 participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, Michigan Peer Review Organization, and the University of Michigan Health System.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Adults with systolic heart failure. Southfield (MI): Michigan Quality Improvement Consortium; 2011 Jan. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.mqic.org/pdf/mqic_adults_with_systolic_heart_failure_cpg.pdf&quot; title=&quot;Michigan Quality Improvement Consortium Web site&quot;&gt;Michigan Quality Improvement Consortium Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on April 14, 2004. The information was verified by the guideline developer on July 27, 2004. This NGC summary was updated by ECRI on February 24, 2005. The information was verified by the guideline developer on February 25, 2005. This NGC summary was updated by ECRI Institute on June 8, 2009. The updated information was verified by the guideline developer on June 30, 2009. This NGC summary was updated by ECRI Institute on May 13, 2011. The updated information was verified by the guideline developer on June 2, 2011. This NGC summary was updated by ECRI Institute on January 15, 2014. The updated information was verified by the guideline developer on February 11, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
